Monjazeb AM, Ayala D, Jensen C, Case LD, Bourland JD, Ellis TL, McMullen KP, Chan MD, Tatter SB, Lesser GJ, Shaw EG. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012;82(2):743-748.

Ruiz J, Case D, Enevold G, Rosdhal R, Tatter SB, Ellis TL, McQuellon RP, McMullen KP, Stieber VW, Shaw EG, Lesser GJ. A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. J Neurooncol. 2012;106(3):611-617.

Geer CP, Simonds J, Anvery A, Chen MY, Burdette JH, Zapadka ME, Ellis TL, Tatter SB, Lesser GJ, Chan MD, McMullen KP, Johnson AJ. Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study. AJNR Am J Neuroradiol. 2012;33(3):556-562.

Renfrow JJ, DeTroye A, Chan M, Tatter S, Ellis T, McMullen K, Johnson A, Mott R, Lesser GJ. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report. J Neurooncol. 2012;107(3):659-663.

Garcia-Espinosa MA, Lesser GJ, Debinski W, Tallant EA, Gallagher PE. Angiotensin-(1-7), a peptide hormone with therapeutic potential for the treatment of glioblastomas [abstract]. In: Proceedings of the 103rd Annual Meeting of the Amerian Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR. 2012;():Abstr 1938.

Hawkins ES, Aiken R, Chandler J, Fink KL, Glantz MJ, Grewal J, Gruber ML, Kesari S, Landolfi JC, LaRocca RV, Lesser GJ, Markert J, Mayer TM, O'Rourke D, Peereboom DM, Phuphanich S, Schiff D, Sloan AE, Stea B, Zhu J-J. A randomized, double-blind, controlled phase IIb study of the safety and efficacy of ICT-107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation [abstract]. J Clin Oncol. 2012;30(15 Suppl):TPS2107.

Sams K, Case LD, Lesser GJ, Naughton MJ, Williford SK, Giguere JK, Garino A, Vitolins M, Shaw EG. Comparing three validated methods of patient self-reported fatigue in a prospective randomized clinical trial [abstract]. J Clin Oncol. 2012;30(15 Suppl):Abstr 9108.

Attia A, Rapp SR, Case LD, D'Agostino R, Lesser G, Naughton M, McMullen K, Rosdhal R, Shaw EG. Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. J Neurooncol. 2012;109(2):357-363.

High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10(5):195-201.

Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012;118(22):5601-5607.

Leyrer M, Chan MD, Peiffer AM, Horne E, Harmon M, Carter AF, Hinson WH, Duncan SE, Dietrich AM, Lesser GJ. Radiation-induced taste and smell toxicity: a dose-volume histogram analysis of a prospective observational study [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S302.

Paulsson A, Peiffer AM, McMullen KP, Hinson WH, Lesser GJ, Ellis TL [deceased], Tatter SB, Shaw EG, Chan MD. Comparison of clinical outcomes for single focus and multifocal glioblastoma [abstract]. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S274.

Strowd RE, Swett K, Harmon M, Pop-Vicas A, Chan M, Tatter SB, Ellis TL [deceased], Blevins M, High K, Lesser GJ. A pilot study of influenza vaccine immunogenicity in patients with malignant central nervous system (CNS) tumors [abstract]. Neuro Oncol. 2012;14(Suppl 6):154.

Strowd RE III, Knovich MA, Lesser GJ. The therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies. Curr Treat Options Oncol. 2012;13(4):451-464.

Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma [editorial]. Neurology. 2011;76(10):929-930.

Kota G, Gupta P, Wilson J, Lesser G, Mintz A. Metastatic intracranial hemangiopericytoma: the role of octreotide and PET imaging in diagnosis, pre-treatment and follow-up evaluation [abstract]. J Nucl Med. 2011;52(Suppl 1):abstr 1065.

Chan MD, Attia A, Tatter SB, Lesser G, Zapadka ME, Mott RT, Carter A, McMullen KP, Shaw EG, Ellis TE [sic ] [Ellis TL]. Radiation-induced adult medulloblastoma: a two-case report and review of the literature. J Neurooncol. 2011;103(3):745-749.

Lamar Z, Lesser GJ. Management of meningeal neoplasms: meningiomas and hemangiopericytomas. Curr Treat Options Oncol. 2011;12(3):230-239.

Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473-5480.

Batchelor T, Grossman S, Brem S, Lesser G, Voloschin A, Nabors LB, Mikkelsen T, Desideri S, Supko J, Peereboom D. Feasibility and phase I/II trial of tandutinib in patients with recurrent glioblastoma [abstract]. Neuro Oncol. 2011;13(Suppl 3):89.

Cole VR, Kennedy LD, Lesser G. Risk factors and treatment for post-dural puncture headache in oncology patients [abstract]. Neuro Oncol. 2011;13(Suppl 3):94.

Paulsson AK, Chan MD, Peiffer AM, Hinson WH, Kearns WT, Lesser GJ, Ellis TL, Tatter SB, Shaw EG, McMullen KP. Decreased CTV margin size does not affect patterns of failure for glioblastoma treated with concurrent radiotherapy and temozolomide [abstract]. Int J Radiat Oncol Biol Phys. 2011;81(2 Suppl):S183.

Lesser GJ, Vitolins MZ. Coenzyme Q10. Oncology (Williston Park). 2011;25(10 Suppl Nurse Edition):10165.

Lesser GJ, Case LD, Mirlohi S, Harmon M, Chan M, Duncan S, Dietrich A. Taste and smell abnormalities (TSA) in patients with newly diagnosed malignant gliomas (MG) treated with combined modality therapy (CMT) [abstract]. J Clin Oncol. 2011;29(15 Suppl):e19646.

Hammond S, Norden AD, Lesser GJ, Drappatz J, Fadul CE, Batchelor T, Quant EC, Beroukhim R, Muzikansky A, Ciampa AS, Doherty LM, LaFrankie DC, Ruland S, Bochacki CA, Griffin K, Gerard M, Sceppa C, Rosenfeld MR, Wen PY. Phase II study of dose-intense temozolomide in recurrent glioblastoma [abstract]. J Clin Oncol. 2011;29(15 Suppl):2038.

Norden AD, Hammond S, Drappatz J, Phuphanich S, Reardon DA, Wong E, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor T, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciampa AS, Doherty LM, Smith KH, Gerard M, Sceppa C, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma [abstract]. J Clin Oncol. 2011;29(15 Suppl):2040.

Attia A, Case LD, D'Agostino R Jr, Lesser GJ, McMullen K, Naughton MJ, Rapp SR, Rosdhal R, Shaw EG. Phase II study of ginkgo biloba in irradiated brain tumor survivors: effects on quality of life (QOL), mood, and cognitive function [abstract]. J Clin Oncol. 2010;28(Suppl):e12523.

Case LD, Naughton MJ, Lesser GJ, Rapp SR, Vitolins M, Sheidler VR, Enevold GL, Shaw EG. Recruitment and retention in the Wake Forest University CCOP Research Base [abstract]. J Clin Oncol. 2010;28(Suppl):e19543.

Naughton MJ, Case LD, Meyers CA, Loghin ME, Shaw EG, Saphner TJ, Sleckman BG, Giguere JK, Lesser GJ, Rapp SR. Quality of life (QOL) and cognitive performance among irradiated brain cancer patients [abstract]. J Clin Oncol. 2010;28(Suppl 7):abstr 9131.

Lesser GJ, Case LD, Stark N, Williford SK, Giguere JK, Garino A, Naughton MJ, Vitolins M, Lively M, Shaw EG. A randomized double-blind placebo-controlled study of oral coenzyme Q10 to relieve self-reported cancer-treatment-related fatigue in newly diagnosed breast cancer patients [abstract]. J Clin Oncol. 2010;28(15 Suppl):9006.

Grossman SA, Ye X, Lesser GJ, Sloan AE, Carson C, Piantadosi S. Iatrogenic immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide: a NABTT CNS Consortium study [abstract]. J Clin Oncol. 2010;28(15 Suppl):2013.

Vitolins M, Lesser GJ, Case LD, Williford SK, Giguere JK, Garino A, Naughton MJ, Lively M, Melin SA, Shaw EG. Self-reported compliance compared to biomarker levels of vitamin E in breast cancer patients participating in a CoQ10 clinical trial [abstract]. J Clin Oncol. 2010;28(15 Suppl):e19524.

Nabors LB, Fink K, Reardon DA, Lesser GJ, Trusheim J, Raval SN, Hicking C, Picard M, Mikkelsen T. Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter: protocol of a multicenter, randomized, open-label, controlled phase II study [abstract]. J Clin Oncol. 2010;28(15 Suppl):TPS151.

High KP, Case LD, Siegel RD, Metzner-Sidurski J, Krauss JC, Chinnasami B, Sanders GH, Rousey S, Lesser GJ, Shaw EG. A phase III randomized, double-blind, placebo controlled trial of North American (NA) ginseng (Panax quinquefolium) extract (CVT-E002) in patients with chronic lymphocytic leukemia: effect on respiratory infection and antibiotic use [abstract]. J Clin Oncol. 2010;28(15 Suppl):6578.

Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 2010;12(10):1071-1077.

Chan MD, Tatter SB, Lesser G, Shaw EG. Radiation oncology in brain tumors: current approaches and clinical trials in progress. Neuroimaging Clin N Am. 2010;20(3):401-408.

Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelson T, Fisher J, Desideri S, He X, et al. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol. 2010;100(2):261-268.

Hammond SN, Norden AD, Drappatz J, Phuphanich S, Reardon D, Wong ET, Plotkin SR, Lesser G, Mintz A, Raizer JJ, et al. Phase II study of monthly pasireotide LAR (Som230C) for recurrent or progressive meningioma [abstract]. Neuro Oncol. 2010;12(Suppl 4):71.

Renfrow J, De Troye A, Chan M, Tatter S, Ellis T, McMullen K, Johnson A, Mott R, Lesser GJ. Initial clinical experience with bendamustine in patients with recurrent primary central nervous system lymphoma (R-PCNSL) [abstract]. Neuro Oncol. 2010;12(Suppl 4):56.

Norden AD, Lesser G, Hammond SN, Drappatz J, Fadul CE, Batchelor TT, Quant EC, Beroukhim R, Ciampa A, Doherty L, et al. Phase II study of dose-intense temozolomide in recurrent glioblastoma [abstract]. Neuro Oncol. 2010;12(Suppl 4):iv71.

Hong JH, Omur-Ozbek P, Stanek BT, Dietrich AM, Duncan SE, Lee YW, Lesser G. Taste and odor abnormalities in cancer patients. J Support Oncol. 2009;7(2):58-65.

Fiveash J, Nabors LB, Mikkelsen T, Peereboom DM, Lesser GJ, Chowdhary SA, Grossman S, Ye X, Leopold L, Rosenfeld M. A phase I study of AT-101 plus radiotherapy and temozolomide and AT-101 plus adjuvant temozolomide for patients with newly diagnosed glioblastoma multiforme [abstract]. Neuro Oncol. 2009;11(5):666.

Lesser GJ, Blackwood R, Harmon M. Temozolomide-induced semen analysis: changes in men with newly diagnosed or recurrent malignant glioma [abstract]. Neuro Oncol. 2009;11(5):658.

Ruiz J, Lesser GJ. Low-grade gliomas. Curr Treat Options Oncol. 2009;10(3-4):231-242.

Lesser GJ, Carver KA, Newton SJ, Tallant EA, Gallagher PE. Angiotensin-(1-7), a small molecule inhibitor of glioblastoma growth [abstract]. J Clin Oncol. 2009;27(15 Suppl):2024.

Fiveash JB, Chowdhary SA, Peereboom D Jr, Mikkelsen T, Nabors LB, Lesser GJ, Rosenfeld MR, Ye X, Grossman SA. A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM) [abstract]. J Clin Oncol. 2009;27(15 Suppl):2010.

Nabors LB, Mikkelson T, Batchelor T, Lesser G, Rosenfeld M, Ye X, Piantadosi S, Olson J, Brem S, Grossman S. A randomized phase II trial of EMD 121974 in conjunction with concomitant and adjuvant temozolomide with radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) [abstract]. J Clin Oncol. 2009;27(15 Suppl):2001.

Rosenfeld MR, Chamberlain M, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A phase II study of chemoradiation followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma: 12- and 18- month survival data [abstract]. J Clin Oncol. 2009;27(15 Suppl):2002.

Supko JG, Grossman SA, Peereboom DM, Chowdhary S, Lesser GJ, Nabors LB, Mikkelson T, Desideri S, Batchelor TT. Feasibility and phase I trial of tandutinib in patients with recurrent glioblastoma [abstract]. J Clin Oncol. 2009;27(15 Suppl):2039.

Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol. 2008;10(2):190-198.

Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol. 2008;9(1):23-31.

Phuphanich S, Carson KA, Grossman SA, Lesser G, Olson J, Mikkelsen T, Desideri S, Fisher JD. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol. 2008;10(4):617-623.

Grossman SA, Carson KA, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro Oncol. 2008;10(4):608-616.

Monjazeb AM, Bourland JD, Case LD, Ellis TL, Lesser GJ, McMullen KP, Munley M, Tatter SB, Shaw EG. A phase I dose escalation study of IMRT field-in-field boost for newly diagnosed glioblastoma multiforme (GBM) [abstract]. Int J Radiat Oncol Biol Phys. 2008;72(1 Suppl 1):S227.

Lesser G, Carver K, Newton S, Tallant EA, Gallagher P. Angiotensin-(1-7) inhibits the growth of human glioblastoma xenografts in nude mice [abstract]. Neuro Oncol. 2008;10(5):792.

Lustig R, Mikkelsen T, Lesser G, Grossman S, Ye X, Desideri S, Fisher J, Wright J. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol. 2008;10(6):1004-1009.

Streiff MB, Grossman SA, Ye X, Kickler TS, Lesser GJ, Batchelor TT, Jani JT, Desideri S. Elevated factor VIII activity is common in patients with newly diagnosed high-grade gliomas [abstract]. J Clin Oncol. 2008;26(15 Suppl Pt I):97s.

Batchelor TT, Lesser GJ, Grossman SA. Rituximab monotherapy for relapsed or refractory primary central nervous system lymphoma [abstract]. J Clin Oncol. 2008;26(15 Suppl Pt I):99s.

Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A phase II trial of radiation plus temozolomide followed by adjuvant temozolomide and poly-ICLC in patients with newly diagnosed glioblastoma multiforme (NABTT #0501) [abstract]. J Clin Oncol. 2008;26(15 Suppl Pt I):102s.

Murray CE, D'Agostino R Jr, Lesser GJ. Retreatment with a prolonged temozolomide (TMZ) dosing schedule in patients (pts) with recurrent malignant gliomas (MG) [abstract]. J Clin Oncol. 2008;26(15 Suppl Pt I):108s.

Lesser GJ, Case D, Ottery F, McQuellon R, Choksi JK, Sanders G, Rosdhal R, Shaw EG. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy [abstract]. J Clin Oncol. 2008;26(15 Suppl Pt I):505s.

Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007;2(5):445-449.

Grossman SA, Desideri S, Ye X, Szajna K, Chamberlain M, Lesser G. Iatrogenic immunosuppression in patients with newly diagnosed high-grade gliomas [abstract]. J Clin Oncol. 2007;25(18 Suppl Pt I):78s.

Lesser GJ, Stieber V, Case D, Enevold G, Rosdhal R, Tatter S, Ellis T, McMullen K, Shaw E. A phase II trial of thalidomide (Thal) and procarbazine (Pro) in adults with recurrent or progressive malignant gliomas (MG) [abstract]. J Clin Oncol. 2007;25(18 Suppl Pt I):91s.

Phuphanich S, Chamberlain M, Mikkelsen T, Ye X, Grossman SA, Batchelor T, Lesser G, Fisher JD, Desideri S. A phase I study of SDX-102 for the treatment of patients with MTAP-deficient recurrent malignant gliomas [abstract]. J Clin Oncol. 2007;25(18 Suppl Pt I):90s.

Grossman S, Desideri S, Piantadosi S, Lesser G, Chamberlain M, Ye XB. Treatment-induced immunosuppression in newly diagnosed high-grade gliomas: a NABTT CNS consortium study [abstract]. Neuro Oncol. 2007;9(4):521.

Voelzke WR, Graves JT, Hemphill MB, Gibo DM, Debinski W, Petty WJ, Lesser G. Pre-clinical evaluation of erlotinib and 13-cis-retinoic acid for the treatment of malignant gliomas [abstract]. Neuro Oncol. 2007;9(4):492.

Butler JM Jr, Case LD, Frizzell B, Lesser G, McMullen K, McQuellon R, Naughton M, Rapp S, Stieber V, Shaw EG, et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys. 2007;69(5):1496-1501.

Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006;12(17):5174-5181.

Peacock KH, Lesser GJ. Current therapeutic approaches in patients with brain metastases. Curr Treat Options Oncol. 2006;7(6):479-489.

Phuphanich S, Supko J, Carson KA, Grossman SA, Nabors LB, Mikkelsen T, Lesser G, Rosenfeld M, Desideri S, Olson J. Phase I trial of bortezomib in adults with recurrent malignant glioma [abstract]. J Clin Oncol. 2006;24(18 Suppl Pt I):74s.

Phuphanich S, Supko J, Carson KA, Grossman SA, Nabors LB, Mikkelsen T, Lesser G, Rosenfeld M, Desideri S, Olson J. A phase I evaluation of the safety of bortezomib with biologic proteosome 20S activity correlation and the effects of anticonvulsants in adults with recurrent malignant glioma [abstract]. Neuro Oncol. 2006;8(4):449.